Q-omics provides the consensus-scored SCARNA14 profile across patient tissues and cancer cell-line models. SCARNA14 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SCARNA14 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, SCARNA14 RNA expression shows 6,968 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, BRCA, and LSCC as cancer lineages where SCARNA14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCARNA14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCARNA14 survival associations across molecular data types. SCARNA14 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCARNA14 RNA expression–survival associations across cancer types. High SCARNA14 expression shows unfavorable associations in ACC, LUSC, THCA and TGCT, but favorable associations in BLCA and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SCARNA14 RNA expression.
This table summarizes SCARNA14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SCARNA14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCARNA14 shows higher tumor expression in BRCA, LUSC, COAD, HNSC, STAD and ESCA. The BRCA box plot shows higher SCARNA14 RNA expression in tumor versus normal tissue (log2 FC = +0.128, t-test p = .043).
This table shows molecular features associated with SCARNA14 in patient tissues and cancer cell lines. In patient samples, SCARNA14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
